Skip to content

Xencor XNCR Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Amgen logo
AmgenAMGN
-$959M-9.7%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$2.03M-217%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$4.67M+77.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$1.5M+12.1%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$10.19M-453%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$12.22M+658%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+79.8%
Enterprise value$1.23B+58.6%
P/S11×+6.3×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's change in accrued liabilities?
Xencor (XNCR) reported change in accrued liabilities of -$707K in Q1 2026.
How has Xencor's change in accrued liabilities changed year-over-year?
Xencor's change in accrued liabilities increased by 77.6% year-over-year, from -$3.15M to -$707K.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.